(iTunes or Listen Here)

In a prior FOAMcastini, we covered the updated ACEP tPA clinical policy. As residents, we sought perspectives from experts, the FOAMcast brain trust (Drs. Anand Swaminathan, Ken Milne, Ryan Radecki, and David Newman).  We (Jeremy) also interviewed Dr. Jerry Hoffman, faculty at UCLA.

In this interview, Dr. Jerry Hoffman, a public skeptic and author of peer reviewed critiques of tPA provides interesting perspective on more than thrombolysis but on the future of guidelines (referencing this paper) and science in Emergency Medicine.

A few of Dr. Hoffman’s articles on the topic:

Ensuring the integrity of clinical practice guidelines: a tool for protecting patients.

How is more negative evidence being used to support claims of benefit: The curious case of the third international stroke trial (IST-3).

Thrombolysis for stroke: policy should be based on science, and not on politics, money or fear of malpractice.

Stroke thrombolysis: we need new data, not more reviews.

Against: And just what is the emperor of stroke wearing?

Thrombolytic therapy for acute ischemic stroke – Tissue plasminogen activator for acute ischemic stroke: Is the CAEP Position Statement too negative?